X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CIPLA JUBILANT LIFE SCIENCES/
CIPLA
 
P/E (TTM) x 16.6 39.2 42.3% View Chart
P/BV x 4.4 3.6 120.9% View Chart
Dividend Yield % 0.4 0.5 88.8%  

Financials

 JUBILANT LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
CIPLA
Mar-18
JUBILANT LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs187663 28.2%   
Low Rs65479 13.6%   
Sales per share (Unadj.) Rs364.3189.0 192.7%  
Earnings per share (Unadj.) Rs6.817.6 38.9%  
Cash flow per share (Unadj.) Rs24.534.0 72.0%  
Dividends per share (Unadj.) Rs3.003.00 100.0%  
Dividend yield (eoy) %2.40.5 453.4%  
Book value per share (Unadj.) Rs164.9176.7 93.3%  
Shares outstanding (eoy) m159.28805.12 19.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.4%   
Avg P/E ratio x18.432.5 56.7%  
P/CF ratio (eoy) x5.116.8 30.6%  
Price / Book Value ratio x0.83.2 23.6%  
Dividend payout %43.817.1 257.0%   
Avg Mkt Cap Rs m20,061459,724 4.4%   
No. of employees `0006.223.6 26.2%   
Total wages/salary Rs m11,05226,901 41.1%   
Avg. sales/employee Rs Th9,383.06,446.1 145.6%   
Avg. wages/employee Rs Th1,786.91,139.4 156.8%   
Avg. net profit/employee Rs Th176.3600.0 29.4%   
INCOME DATA
Net Sales Rs m58,034152,193 38.1%  
Other income Rs m1913,577 5.3%   
Total revenues Rs m58,224155,769 37.4%   
Gross profit Rs m5,78628,264 20.5%  
Depreciation Rs m2,81213,228 21.3%   
Interest Rs m3,2371,142 283.4%   
Profit before tax Rs m-7217,470 -0.4%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m2,145-775 -276.7%   
Tax Rs m6962,501 27.8%   
Profit after tax Rs m1,09014,166 7.7%  
Gross profit margin %10.018.6 53.7%  
Effective tax rate %-965.914.3 -6,746.5%   
Net profit margin %1.99.3 20.2%  
BALANCE SHEET DATA
Current assets Rs m29,280108,141 27.1%   
Current liabilities Rs m38,91238,322 101.5%   
Net working cap to sales %-16.645.9 -36.2%  
Current ratio x0.82.8 26.7%  
Inventory Days Days8497 87.0%  
Debtors Days Days5174 68.1%  
Net fixed assets Rs m55,712109,411 50.9%   
Share capital Rs m1551,610 9.6%   
"Free" reserves Rs m20,968140,682 14.9%   
Net worth Rs m26,265142,292 18.5%   
Long term debt Rs m17,16936,621 46.9%   
Total assets Rs m88,606228,606 38.8%  
Interest coverage x1.016.3 6.0%   
Debt to equity ratio x0.70.3 254.0%  
Sales to assets ratio x0.70.7 98.4%   
Return on assets %4.96.7 72.9%  
Return on equity %4.210.0 41.7%  
Return on capital %11.610.0 116.2%  
Exports to sales %37.832.8 115.3%   
Imports to sales %16.50-   
Exports (fob) Rs m21,93349,883 44.0%   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00451,691 42.6%   
Fx outflow Rs m11,74921,033 55.9%   
Net fx Rs m10,25530,658 33.5%   
CASH FLOW
From Operations Rs m8,02614,628 54.9%  
From Investments Rs m-1,744-8,540 20.4%  
From Financial Activity Rs m-4,447-3,855 115.4%  
Net Cashflow Rs m1,8342,431 75.5%  

Share Holding

Indian Promoters % 45.6 16.0 285.0%  
Foreign collaborators % 3.5 20.8 16.8%  
Indian inst/Mut Fund % 8.7 12.2 71.3%  
FIIs % 21.2 23.7 89.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.1 26.2 80.5%  
Shareholders   23,815 161,166 14.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 14, 2018 01:57 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS